Literature DB >> 16175089

Obstacles to the early detection of endocervical adenocarcinoma.

T Kalir1, A Simsir, H B Demopoulos, R I Demopoulos.   

Abstract

We observed that the ratio of in situ to invasive carcinomas of the cervix is significantly greater for squamous than for glandular lesions. We wondered whether Pap smears were less effective for the identification of in situ glandular lesions. The purpose of this study was to determine if the location, extent of disease, and growth patterns of endocervical adenocarcinomas influence the ability to detect malignant cells by Pap smears. Medical records, doctor's office records, and all pathology materials (reports and slides) including Pap smears, biopsies, LEEP/cone biopsies, and hysterectomy specimens from 53 consecutive patients diagnosed with endocervical adenocarcinomas were examined at New York University Medical Center (a total of 654 pathology slides and 51 Pap smears were reviewed). Findings were correlated for each patient using gross descriptions and histopathology and stratified by location/extent of disease and growth pattern (exophytic or endophytic or both). Ten patients had in situ disease, seven (70%) of which involved the transformation zone (TZ); all seven of these were identified by Pap smears. In contrast, of the other three cases that did not involve the TZ but were confined to the endocervix, only one was identified by Pap smear. Forty-three patients had invasive disease. Twenty involved the TZ, and 23 involved the endocervix but spared the TZ. Of the 20 tumors involving the TZ, 11 (55%) were identified by Pap smears, whereas of the 23 sparing the TZ, 11 (47.8%) were diagnosed by Pap smear. Among the 23 patients with invasive disease that spared the TZ, 6 (26%) had a documented history of negative Pap smears at New York University within 3 years of diagnosis. Conversely only 1 of the 20 patients with TZ involvement had a history of negative Pap smears, and 3 patients in this group denied having had Pap smears for several years. Including all 53 patients, a significantly higher proportion were not detectable by Pap smear if the TZ was spared (54% versus 25%, p = 0.036). Of the 23 invasive cancers that spared the TZ, 6 (14%) had verified negative Pap smears. These lesions did not shed malignant cells onto Pap smears. Noteworthy was the finding that two of these six lesions extended from the endocervix upward, through the stroma, and into the endomyometrium of the lower uterine segment. Four extended downward into the exocervix through the stroma, sparing the surface mucosa; one reached the upper vagina. All six displayed an endophytic growth pattern.

Entities:  

Mesh:

Year:  2005        PMID: 16175089     DOI: 10.1097/01.pgp.0000170067.73452.72

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  4 in total

1.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

2.  Detection of in situ and invasive endocervical adenocarcinoma on ThinPrep Pap Test: Morphologic analysis of false negative cases.

Authors:  Michael Chaump; Edyta C Pirog; Vinicius J A Panico; Alexandre Buckley D Meritens; Kevin Holcomb; Rana Hoda
Journal:  Cytojournal       Date:  2016-12-20       Impact factor: 2.091

3.  Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003.

Authors:  H P van de Nieuwenhof; L F A G Massuger; J A de Hullu; M A P C van Ham; J A A M van Dijck; A G Siebers; R L M Bekkers
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

4.  A case of endocervical adenocarcinoma detected 16 months after vaginal delivery.

Authors:  İpek Ulu; Esra Tuştaş Haberal; Mehmet Serdar Gülşen; Eser Evrim Yoğurtçuoğlu; Gürkan Kıran; Yasemin Çekmez; Gözde Kır
Journal:  Clin Case Rep       Date:  2016-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.